<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231114011057&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231114011057&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 14 Nov 2023 06:10:58 +0000</lastbuilddate>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 13. doi: 10.1038/s41569-023-00959-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37957335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37957335</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00959-y>10.1038/s41569-023-00959-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37957335</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Disrupting a cell-specific miRNA-CXCR4 interaction is atheroprotective in mice</dc:title>
<dc:identifier>pmid:37957335</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00959-y</dc:identifier>
</item>
<item>
<title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 8:S0735-1097(23)07988-3. doi: 10.1016/j.jacc.2023.11.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the ISCHEMIA trial, the risk of ischemic events was similar in patients with stable coronary artery disease treated with an invasive (INV) strategy of angiography and percutaneous (PCI) or surgical (CABG) coronary revascularization and a conservative (CON) strategy of initial medical therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To analyze separately the outcomes of INV patients treated with PCI or CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients without preceding primary outcome events were categorized as INV-PCI or INV-CABG from the time of revascularization. The ISCHEMIA primary outcome (composite of cardiovascular death, protocol-defined myocardial infarction (MI) or hospitalization for unstable angina, heart failure or resuscitated cardiac arrest) was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among INV-CABG patients, primary outcome events occurred in 84/512 (16.4%) at median follow-up of 2.85 years; 48 events (57.1%) occurred within 30 days after CABG, including 40 procedural MIs; among INV-PCI patients, primary outcome events occurred in 147/1500 (9.8%) at median follow-up of 2.94 years; 31 of which (21.1%) within 30 days after PCI, including 23 procedural MIs. In comparison, 352/2591 (13.6%) CON patients had primary outcome events at median follow-up 3.2 years, 22 of which (6.3%) within 30 days of randomization. The adjusted primary outcome risks (HR [95%CI]) were higher after both CABG and PCI within 30 days (16.25 (11.44-23.07) and 2.99 (1.97-4.53)) and lower thereafter (0.63 (0.44-0.89) and 0.66(0.53-0.82)).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ISCHEMIA, early revascularization by PCI and CABG was associated with higher early risks and lower long-term risks of cardiovascular events compared with CON. The early risk was greatest after CABG, due to protocol-defined procedural MIs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956961</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.002>10.1016/j.jacc.2023.11.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956961</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Eric R Bates</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Giuseppe Biondi-Zoccai</dc:creator>
<dc:creator>Tulio Caldonazo</dc:creator>
<dc:creator>Michael Farkouh</dc:creator>
<dc:creator>Mohamed Rahouma</dc:creator>
<dc:creator>John Puskas</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Mario Fl Gaudino</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:37956961</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.002</dc:identifier>
</item>
<item>
<title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 13:ehad770. doi: 10.1093/eurheartj/ehad770. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: ECG abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD) but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study population was drawn from two prospective community-based SCD studies in Oregon, USA (2002-, discovery cohort) and California, USA (2015-, validation cohort). For this present sub-study, 231 discovery cases (2015-2017) and 203 validation cases (2015-2021) with ≥2 archived pre-SCD ECGs were ascertained, and were matched to 234 discovery and 203 validation controls based on age, sex, and duration between the ECGs. Dynamic ECG remodeling was measured as progression of a previously validated cumulative 6-variable ECG electrical risk score (ERS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Oregon SCD cases displayed greater ERS increase over time vs. controls [+1.06 (95% CI +0.89 to +1.24) vs. -0.05 (-0.21 to +0.11); p &lt; 0.001]. These findings were successfully replicated in California [+0.87 (+0.7 to +1.04) vs. -0.11 (-0.27 to 0.05); p &lt; 0.001]. In multivariable models, abnormal dynamic ECG remodeling improved SCD prediction over baseline ECG, demographics, and clinical SCD risk factors in both Oregon [AUC 0.770 (95% CI 0.727-0.812) increased to AUC 0.869 (95% CI 0.837-0.902)] and California cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dynamic ECG remodeling improved SCD risk prediction beyond clinical factors combined with the static ECG, with successful validation in a geographically distinct population. These findings introduce a novel concept of SCD dynamic risk and warrant further detailed investigation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956651</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad770>10.1093/eurheartj/ehad770</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956651</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>H N Pham</dc:creator>
<dc:creator>L Holmstrom</dc:creator>
<dc:creator>H Chugh</dc:creator>
<dc:creator>A Uy-Evanado</dc:creator>
<dc:creator>K Nakamura</dc:creator>
<dc:creator>Z Zhang</dc:creator>
<dc:creator>A Salvucci</dc:creator>
<dc:creator>J Jui</dc:creator>
<dc:creator>K Reinier</dc:creator>
<dc:creator>S S Chugh</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dynamic ECG Changes Are a Novel Risk Marker for Sudden Cardiac Death</dc:title>
<dc:identifier>pmid:37956651</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad770</dc:identifier>
</item>
<item>
<title>Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 12:ehad771. doi: 10.1093/eurheartj/ehad771. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with long atrial high-rate episodes (AHRE) ≥ 24 hours and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared to no anticoagulation in these patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This secondary prespecified analysis of NOAH-AFNET 6 examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared to placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and ECG-diagnosed atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AHRE ≥24 hours were present at baseline in 259/2389 patients enrolled in NOAH-AFNET 6 (11%, 78 ± 7 years old, 28% women, CHA2DS2-VASc score 4). Clinical characteristics were not different from patients with shorter AHRE. During a median follow-up of 1.8 years, the primary outcome occurred in 9/132 patients with AHRE ≥24 hours (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). AHRE duration did not interact with the efficacy (p-interaction = 0.65) or safety (p-interaction = 0.98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE ≥24 hours developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; p &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956458</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad771>10.1093/eurheartj/ehad771</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956458</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>Tobias Toennis</dc:creator>
<dc:creator>Emanuele Bertaglia</dc:creator>
<dc:creator>Carina Blomström-Lundqvist</dc:creator>
<dc:creator>Axel Brandes</dc:creator>
<dc:creator>Nuno Cabanelas</dc:creator>
<dc:creator>Melanie Calvert</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Gregory Chlouverakis</dc:creator>
<dc:creator>Gheorghe-Andrei Dan</dc:creator>
<dc:creator>Wolfgang Dichtl</dc:creator>
<dc:creator>Hans Christoph Diener</dc:creator>
<dc:creator>Alexander Fierenz</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Joris R de Groot</dc:creator>
<dc:creator>Astrid N L Hermans</dc:creator>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Andrzej Lubinski</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Lluís Mont</dc:creator>
<dc:creator>Ann-Kathrin Ozga</dc:creator>
<dc:creator>Kim Rajappan</dc:creator>
<dc:creator>Andrea Sarkozy</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Susanne Sehner</dc:creator>
<dc:creator>Emmanuel Simantirakis</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Vasil Velchev</dc:creator>
<dc:creator>Dan Wichterle</dc:creator>
<dc:creator>Antonia Zapf</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours</dc:title>
<dc:identifier>pmid:37956458</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad771</dc:identifier>
</item>
<item>
<title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):e185. doi: 10.1161/CIR.0000000000001190. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956227</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001190>10.1161/CIR.0000000000001190</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956227</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:37956227</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001190</dc:identifier>
</item>
<item>
<title>Risk Stratification in Brugada Syndrome: How Low Can We Go?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1556-1558. doi: 10.1161/CIRCULATIONAHA.123.066697. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956226</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066697>10.1161/CIRCULATIONAHA.123.066697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956226</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Johan Saenen</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk Stratification in Brugada Syndrome: How Low Can We Go?</dc:title>
<dc:identifier>pmid:37956226</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066697</dc:identifier>
</item>
<item>
<title>Letter by Zhang et al Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1602-1603. doi: 10.1161/CIRCULATIONAHA.123.066427. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956225</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066427>10.1161/CIRCULATIONAHA.123.066427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956225</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Man-Ru Zhang</dc:creator>
<dc:creator>Dan-Dan Guo</dc:creator>
<dc:creator>Jing Zhao</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhang et al Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</dc:title>
<dc:identifier>pmid:37956225</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066427</dc:identifier>
</item>
<item>
<title>Response by Cho and Yoon to Letter Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1604-1605. doi: 10.1161/CIRCULATIONAHA.123.066624. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956224</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066624>10.1161/CIRCULATIONAHA.123.066624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956224</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kyu-Won Cho</dc:creator>
<dc:creator>Young-Sup Yoon</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Cho and Yoon to Letter Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis"</dc:title>
<dc:identifier>pmid:37956224</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066624</dc:identifier>
</item>
<item>
<title>Studying Long QT Syndrome Caused by &lt;em>;NAA10&lt;/em>; Genetic Variants Using Patient-Derived Induced Pluripotent Stem Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1598-1601. doi: 10.1161/CIRCULATIONAHA.122.061864. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956223</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061864>10.1161/CIRCULATIONAHA.122.061864</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956223</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nadjet Belbachir</dc:creator>
<dc:creator>Yiyang Wu</dc:creator>
<dc:creator>Mengcheng Shen</dc:creator>
<dc:creator>Sophia L Zhang</dc:creator>
<dc:creator>Joe Z Zhang</dc:creator>
<dc:creator>Chun Liu</dc:creator>
<dc:creator>Bjorn C Knollmann</dc:creator>
<dc:creator>Gholson J Lyon</dc:creator>
<dc:creator>Ning Ma</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Studying Long QT Syndrome Caused by &lt;em>;NAA10&lt;/em>; Genetic Variants Using Patient-Derived Induced Pluripotent Stem Cells</dc:title>
<dc:identifier>pmid:37956223</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061864</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 14;148(20):1593-1597. doi: 10.1161/CIRCULATIONAHA.123.067572. Epub 2023 Nov 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956222</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067572>10.1161/CIRCULATIONAHA.123.067572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956222</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:37956222</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067572</dc:identifier>
</item>
<item>
<title>A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37956127</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067528>10.1161/CIRCULATIONAHA.123.067528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37956127</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kazuya Hosokawa</dc:creator>
<dc:creator>Hiroko Watanabe</dc:creator>
<dc:creator>Yu Taniguchi</dc:creator>
<dc:creator>Nobutaka Ikeda</dc:creator>
<dc:creator>Takumi Inami</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:creator>Toyoaki Murohara</dc:creator>
<dc:creator>Masaru Hatano</dc:creator>
<dc:creator>Yuichi Tamura</dc:creator>
<dc:creator>Jun Yamashita</dc:creator>
<dc:creator>Koichiro Tatsumi</dc:creator>
<dc:creator>Ichizo Tsujino</dc:creator>
<dc:creator>Yuko Kobayakawa</dc:creator>
<dc:creator>Shiro Adachi</dc:creator>
<dc:creator>Nobuhiro Yaoita</dc:creator>
<dc:creator>Shun Minatsuki</dc:creator>
<dc:creator>Koji Todaka</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Hiroyuki Tsutsui</dc:creator>
<dc:creator>Kohtaro Abe</dc:creator>
<dc:creator>KABUKI Investigators</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial</dc:title>
<dc:identifier>pmid:37956127</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067528</dc:identifier>
</item>
<item>
<title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4776. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Patients were categorized by HF type and further divided by loop diuretic strategy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P &lt; .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P &lt; .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955908</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955908</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Selim R Krim</dc:creator>
<dc:creator>Senthil Anand</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Anqi Chen</dc:creator>
<dc:creator>Daniel Wojdyla</dc:creator>
<dc:creator>Juan Vilaro</dc:creator>
<dc:creator>Herbert Haught</dc:creator>
<dc:creator>John M Herre</dc:creator>
<dc:creator>Eric L Eisenstein</dc:creator>
<dc:creator>Kevin J Anstrom</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37955908</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4776</dc:identifier>
</item>
<item>
<title>Neighborhood Environmental Burden and Cardiovascular Health in the US</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4680. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiovascular disease is the leading cause of death in the US. However, little is known about the association between cumulative environmental burden and cardiovascular health across US neighborhoods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association of neighborhood-level environmental burden with prevalence of cardiovascular risk factors and diseases, overall and by levels of social vulnerability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTINGS, AND PARTICIPANTS: This was a national cross-sectional study of 71 659 US Census tracts. Environmental burden (EBI) and social vulnerability indices from the US Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry were linked to the 2020 CDC PLACES data set. Data were analyzed from March to October 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: The EBI, a measure of cumulative environmental burden encompassing 5 domains (air pollution, hazardous or toxic sites, built environment, transportation infrastructure, and water pollution).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Neighborhood-level prevalence of cardiovascular risk factors (hypertension, diabetes, and obesity) and cardiovascular diseases (coronary heart disease and stroke).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Across the US, neighborhoods with the highest environmental burden (top EBI quartile) were more likely than those with the lowest environmental burden (bottom EBI quartile) to be urban (16 626 [92.7%] vs 13 414 [75.4%]), in the Midwest (5191 [28.9%] vs 2782 [15.6%]), have greater median (IQR) social vulnerability scores (0.64 [0.36-0.85] vs 0.42 [0.20-0.65]), and have higher proportions of adults in racial or ethnic minority groups (median [IQR], 34% [12-73] vs 12% [5-30]). After adjustment, neighborhoods with the highest environmental burden had significantly higher rates of cardiovascular risk factors than those with the lowest burden, including hypertension (mean [SD], 32.83% [7.99] vs 32.14% [6.99]; adjusted difference, 0.84%; 95% CI, 0.71-0.98), diabetes (mean [SD], 12.19% [4.33] vs 10.68% [3.27]; adjusted difference, 0.62%; 95% CI, 0.53-0.70), and obesity (mean [SD], 33.57% [7.62] vs 30.86% [6.15]; adjusted difference, 0.77%; 95% CI, 0.60-0.94). Similarly, neighborhoods with the highest environmental burden had significantly higher rates of coronary heart disease (mean [SD], 6.66% [2.15] vs 6.82% [2.41]; adjusted difference, 0.28%; 95% CI, 0.22-0.33) and stroke (mean [SD], 3.65% [1.47] vs 3.31% [1.12]; adjusted difference, 0.19%; 95% CI, 0.15-0.22). Results were consistent after matching highest and lowest environmentally burdened neighborhoods geospatially and based on other covariates. The associations between environmental burden quartiles and cardiovascular risk factors and diseases were most pronounced among socially vulnerable neighborhoods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cross-sectional study of US neighborhoods, cumulative environmental burden was associated with higher rates of cardiovascular risk factors and diseases, although absolute differences were small. The strongest associations were observed in socially vulnerable neighborhoods. Whether initiatives that address poor environmental conditions will improve cardiovascular health requires additional prospective investigations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955891</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4680>10.1001/jamacardio.2023.4680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955891</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Michael Liu</dc:creator>
<dc:creator>Vishal R Patel</dc:creator>
<dc:creator>Renee N Salas</dc:creator>
<dc:creator>Mary B Rice</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>ZhaoNian Zheng</dc:creator>
<dc:creator>Rishi K Wadhera</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Neighborhood Environmental Burden and Cardiovascular Health in the US</dc:title>
<dc:identifier>pmid:37955891</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4680</dc:identifier>
</item>
<item>
<title>Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Nov 13. doi: 10.1001/jamacardio.2023.4722. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955872</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4722>10.1001/jamacardio.2023.4722</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955872</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Prioritizing the Exposome to Reduce Cardiovascular Disease Burden</dc:title>
<dc:identifier>pmid:37955872</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4722</dc:identifier>
</item>
<item>
<title>Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955620</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067588>10.1161/CIRCULATIONAHA.123.067588</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955620</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>David J Whellan</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume</dc:title>
<dc:identifier>pmid:37955620</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067588</dc:identifier>
</item>
<item>
<title>Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>Background: Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. Methods: The WATCHFUL trial was a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT) in stable patients with HFrEF compared to usual care. <b>Methods:</b> The WATCHFUL trial was a 6-month, multicenter, parallel-group, randomized, controlled trial recruiting HFrEF patients from six Czech cardiovascular centers. Eligible participants were ≥18 years old with left ventricular ejection fraction &lt;40% and NYHA class II/III symptoms, on guidelines-recommended medication, excluding those exceeding 450m in the baseline 6MWT. Patients in the intervention group were equipped with a Garmin vívofit activity tracker and received monthly phone counseling from research nurses who encouraged them to employ behavior change techniques such as self-monitoring, goal-setting, and action planning to increase their daily step count. The control group patients continued usual care. The primary outcome was the difference between groups in the distance (in meters) walked during the 6MWT at 6 months. Secondary outcomes included daily step count and minutes of moderate-to-vigorous physical activity (MVPA) as measured by the hip-worn Actigraph wGT3X-BT accelerometer, NT-proBNP and hsCRP biomarkers, ejection fraction, anthropometric measures, depression score, self-efficacy, quality of life, and survival risk score. The primary analysis was conducted by intention-to-treat. <b>Results:</b> From 218 screened patients, 202 were randomized (65 years; 22.8% female; 90.6% NYHA II; left ventricular ejection fraction 32.5%; 6MWT 385m; 5071 steps/day; 10.9 minutes of MVPA per day). At six months, no between-group differences were detected for the 6MWT (7.4 m, 95% CI -8.0 to 22.7, p=0.345, N=186). The intervention group increased their average daily step count by 1420 (95% CI: 749; 2091) and daily minutes of MVPA by 8.2 (95% CI: 3.0; 13.3) over the control group. No between-group differences were detected for any other secondary outcomes. <b>Conclusions:</b> While the lifestyle intervention in patients with HFrEF improved daily steps by about 25%, it failed to demonstrate a corresponding improvement in functional capacity. Further research is needed to understand the disconnect between increased physical activity and functional outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955615</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067395>10.1161/CIRCULATIONAHA.123.067395</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955615</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tomas Vetrovsky</dc:creator>
<dc:creator>Michal Siranec</dc:creator>
<dc:creator>Tereza Frybova</dc:creator>
<dc:creator>Iulian Gant</dc:creator>
<dc:creator>Iveta Svobodova</dc:creator>
<dc:creator>Ales Linhart</dc:creator>
<dc:creator>Jiri Parenica</dc:creator>
<dc:creator>Marie Miklikova</dc:creator>
<dc:creator>Lenka Sujakova</dc:creator>
<dc:creator>David Pospisil</dc:creator>
<dc:creator>Radek Pelouch</dc:creator>
<dc:creator>Daniela Odrazkova</dc:creator>
<dc:creator>Petr Parizek</dc:creator>
<dc:creator>Jan Precek</dc:creator>
<dc:creator>Martin Hutyra</dc:creator>
<dc:creator>Milos Taborsky</dc:creator>
<dc:creator>Jiri Vesely</dc:creator>
<dc:creator>Martin Griva</dc:creator>
<dc:creator>Miroslav Semerad</dc:creator>
<dc:creator>Vaclav Bunc</dc:creator>
<dc:creator>Karolina Hrabcova</dc:creator>
<dc:creator>Adela Vojkuvkova</dc:creator>
<dc:creator>Michal Svoboda</dc:creator>
<dc:creator>Jan Belohlavek</dc:creator>
<dc:creator>WATCHFUL Investigators</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial</dc:title>
<dc:identifier>pmid:37955615</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067395</dc:identifier>
</item>
<item>
<title>Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>Background: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. Methods: This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.065908. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. <b>Methods:</b> This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search strategies (National Collegiate Athletic Association resolutions list, Parent Heart Watch database and media reports, National Center for Catastrophic Sports Injury Research database, and insurance claims). Autopsy reports and medical history were reviewed by an expert panel to adjudicate causes of SCD. <b>Results:</b> A total of 143 SCD cases in National Collegiate Athletic Association athletes were identified from 1102 total deaths. The National Collegiate Athletic Association resolutions list identified 117 of 143 (82%), the Parent Heart Watch database or media reports identified 89 of 143 (62%), the National Center for Catastrophic Sports Injury Research database identified 63 of 143 (44%), and insurance claims identified 27 of 143 (19%) SCD cases. The overall incidence of SCD was 1:63682 athlete-years (95% CI, 1:54065-1:75010). Incidence was higher in male athletes than in female athletes (1:43348 [95% CI, 1:36228-1:51867] versus 1:164504 [95% CI, 1:110552-1:244787] athlete-years, respectively) and Black athletes compared with White athletes (1:26704 [1:20417-1:34925] versus 1:74581 [1:60247-1:92326] athlete-years, respectively). The highest incidence of SCD was among Division I male basketball players (1:8188 [White, 1:5848; Black, 1:7696 athlete-years]). The incidence rate for SCD decreased over the study period (5-year incidence rate ratio, 0.71 [95% CI, 0.61-0.82]), whereas the rate of noncardiovascular deaths remained stable (5-year incidence rate ratio, 0.98 [95% CI, 0.94-1.04]). Autopsy-negative sudden unexplained death (19.5%) was the most common postmortem examination finding, followed by idiopathic left ventricular hypertrophy or possible cardiomyopathy (16.9%) and hypertrophic cardiomyopathy (12.7%), in cases with enough information for adjudication (118 of 143). Eight cases of death were attributable to myocarditis over the study period (1 case from January 1, 2020, through June 30, 2022), with none attributed to COVID-19 infection. SCD events were exertional in 50% of cases. Exertional SCD was more common among those with coronary artery anomalies (100%) and arrhythmogenic cardiomyopathy (83%). <b>Conclusions:</b> The incidence of SCD in college athletes has decreased. Male sex, Black race, and basketball are associated with a higher incidence of SCD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955565</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065908>10.1161/CIRCULATIONAHA.123.065908</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955565</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bradley J Petek</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Nathaniel Moulson</dc:creator>
<dc:creator>Stephanie A Kliethermes</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Jonathan A Drezner</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Kristen L Kucera</dc:creator>
<dc:creator>David M Siebert</dc:creator>
<dc:creator>Lauren Salerno</dc:creator>
<dc:creator>Monica Zigman Suchsland</dc:creator>
<dc:creator>Irfan M Asif</dc:creator>
<dc:creator>Joseph J Maleszewski</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study</dc:title>
<dc:identifier>pmid:37955565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065908</dc:identifier>
</item>
<item>
<title>Declining Risk of Sudden Cardiac Death in Young Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067243. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067243>10.1161/CIRCULATIONAHA.123.067243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955558</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Domenico Corrado</dc:creator>
<dc:creator>Alessandro Zorzi</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Declining Risk of Sudden Cardiac Death in Young Athletes</dc:title>
<dc:identifier>pmid:37955558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067243</dc:identifier>
</item>
<item>
<title>Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.321836. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary hypertension (PH) is a chronic vascular disease characterized, among other abnormalities, by hyperproliferative smooth muscle cells and a perturbed cellular redox and metabolic balance. Oxidants induce cell cycle arrest to halt proliferation; however, little is known about the redox-regulated effector proteins that mediate these processes. Here, we report a novel kinase-inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in cell proliferation and PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Oxidative modifications of cyclin D-CDK4 were detected in human pulmonary arterial smooth muscle cells and human pulmonary arterial endothelial cells. Site-directed mutagenesis, tandem mass-spectrometry, cell-based experiments, in vitro kinase activity assays, in silico structural modeling, and a novel redox-dead constitutive knock-in mouse were utilized to investigate the nature and definitively establish the importance of CDK4 cysteine modification in pulmonary vascular cell proliferation. Furthermore, the cyclin D-CDK4 oxidation was assessed in vivo in the pulmonary arteries and isolated human pulmonary arterial smooth muscle cells of patients with pulmonary arterial hypertension and in 3 preclinical models of PH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955182</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.321836>10.1161/CIRCRESAHA.122.321836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955182</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Hannah Knight</dc:creator>
<dc:creator>Giancarlo Abis</dc:creator>
<dc:creator>Manpreet Kaur</dc:creator>
<dc:creator>Hannah L H Green</dc:creator>
<dc:creator>Susanne Krasemann</dc:creator>
<dc:creator>Kristin Hartmann</dc:creator>
<dc:creator>Steven Lynham</dc:creator>
<dc:creator>James Clark</dc:creator>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Clemens Ruppert</dc:creator>
<dc:creator>Astrid Weiss</dc:creator>
<dc:creator>Ralph T Schermuly</dc:creator>
<dc:creator>Philip Eaton</dc:creator>
<dc:creator>Olena Rudyk</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</dc:title>
<dc:identifier>pmid:37955182</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.321836</dc:identifier>
</item>
<item>
<title>DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14^(Δ/Δ) mice, by reducing abnormal S/ER clusters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.123.323304. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The p.Arg14del variant of the <i>PLN</i> (phospholamban) gene causes cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear PLN aggregation have both been suggested as pathological drivers of this disease. Dwarf open reading frame (DWORF) has been shown to counteract PLN regulatory calcium handling function in the sarco/endoplasmic reticulum (S/ER). Here, we investigated the potential disease-modulating action of DWORF in this cardiomyopathy and its effects on calcium handling and PLN aggregation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We studied a PLN-R14del mouse model, which develops cardiomyopathy with similar characteristics as human patients, and explored whether cardiac DWORF overexpression could delay cardiac deterioration. To this end, R14<sup>Δ/Δ</sup> (homozygous PLN-R14del) mice carrying the DWORF transgene (R14<sup>Δ/Δ</sup>DWORF<sup>Tg</sup> [R14<sup>Δ/Δ</sup> mice with a copy of the DWORF transgene]) were used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: DWORF expression was suppressed in hearts of R14<sup>Δ/Δ</sup> mice with severe heart failure. Restoration of DWORF expression in R14<sup>Δ/Δ</sup> mice delayed cardiac fibrosis and heart failure and increased life span >;2-fold (from 8 to 18 weeks). DWORF accelerated sarcoplasmic reticulum calcium reuptake and relaxation in isolated cardiomyocytes with wild-type PLN, but in R14<sup>Δ/Δ</sup> cardiomyocytes, sarcoplasmic reticulum calcium reuptake and relaxation were already enhanced, and no differences were detected between R14<sup>Δ/Δ</sup> and R14<sup>Δ/Δ</sup>DWORF<sup>Tg</sup>. Rather, DWORF overexpression delayed the appearance and formation of large pathogenic perinuclear PLN clusters. Careful examination revealed colocalization of sarcoplasmic reticulum markers with these PLN clusters in both R14<sup>Δ/Δ</sup> mice and human p.Arg14del PLN heart tissue, and hence these previously termed aggregates are comprised of abnormal organized S/ER. This abnormal S/ER organization in PLN-R14del cardiomyopathy contributes to cardiomyocyte cell loss and replacement fibrosis, consequently resulting in cardiac dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14<sup>Δ/Δ</sup> mice, by reducing abnormal S/ER clusters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955153</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323304>10.1161/CIRCRESAHA.123.323304</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955153</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nienke M Stege</dc:creator>
<dc:creator>Tim R Eijgenraam</dc:creator>
<dc:creator>Vivian Oliveira Nunes Teixeira</dc:creator>
<dc:creator>Anna M Feringa</dc:creator>
<dc:creator>Elisabeth M Schouten</dc:creator>
<dc:creator>Diederik W D Kuster</dc:creator>
<dc:creator>Jolanda van der Velden</dc:creator>
<dc:creator>Anouk H G Wolters</dc:creator>
<dc:creator>Ben N G Giepmans</dc:creator>
<dc:creator>Catherine A Makarewich</dc:creator>
<dc:creator>Rhonda Bassel-Duby</dc:creator>
<dc:creator>Eric N Olson</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Herman H W Silljé</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</dc:title>
<dc:identifier>pmid:37955153</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323304</dc:identifier>
</item>
<item>
<title>NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231114011057&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.322244. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol (SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of <i>CD47</i> and <i>ROCK2</i> transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231114011057&v=2.17.9.post6+86293ac">37955115</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.322244>10.1161/CIRCRESAHA.122.322244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37955115</guid>
<pubDate>Mon, 13 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jing Shi</dc:creator>
<dc:creator>Chuanxi Yang</dc:creator>
<dc:creator>Kun Zhao</dc:creator>
<dc:creator>Jing Zhang</dc:creator>
<dc:creator>Peng Li</dc:creator>
<dc:creator>Chuiyu Kong</dc:creator>
<dc:creator>Xiaoguang Wu</dc:creator>
<dc:creator>Haoliang Sun</dc:creator>
<dc:creator>Rui Zheng</dc:creator>
<dc:creator>Wei Sun</dc:creator>
<dc:creator>Lianmin Chen</dc:creator>
<dc:creator>Xiangqing Kong</dc:creator>
<dc:date>2023-11-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</dc:title>
<dc:identifier>pmid:37955115</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.322244</dc:identifier>
</item>





























</channel>
</rss>